Alpha 2.0
Login Register
» Authors » Nigel Armstrong

Nigel Armstrong

Explore the profile of Nigel Armstrong including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 67
Citations 816
Followers 0
Related Specialties
Pharmacology
Biotechnology
General Medicine
Top 10 Co-Authors
Jos Kleijnen
Steve Ryder
Rob Riemsma
Gill Worthy
Manuela A Joore
Manuela Joore
Marie Westwood
Steven Duffy
Caro Noake
Bram Ramaekers
Published In
Pharmacoeconomics
Health Technol Assess
BMJ
Radiology
Value Health
Affiliations
Soon will be listed here.
Recent Articles
1.
A cloud-based medical device for predicting cardiac risk in suspected coronary artery disease: a rapid review and conceptual economic model
Westwood M, Armstrong N, Krijkamp E, Perry M, Noake C, Tsiachristas A, et al.
Health Technol Assess . 2024 Jul; 28(31):1-105. PMID: 39023142
Background: The CaRi-Heart® device estimates risk of 8-year cardiac death, using a prognostic model, which includes perivascular fat attenuation index, atherosclerotic plaque burden and clinical risk factors. Objectives: To provide...
2.
Challenges in the Assessment of a Disease Model in the NICE Single Technology Appraisal of Tirzepatide for Treating Type 2 Diabetes: An External Assessment Group Perspective
Scholte M, Ramaekers B, Danopoulos E, Grimm S, Fernandez Coves A, Tian X, et al.
Pharmacoeconomics . 2024 May; 42(8):829-832. PMID: 38717708
No abstract available.
3.
Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR: External Assessment Group Perspective
Sugden B, Grimm S, Wolff R, Armstrong N, Otten T, Abu-Zahra T, et al.
Pharmacoeconomics . 2024 May; 42(6):615-618. PMID: 38713424
No abstract available.
4.
KardiaMobile 6L for measuring QT interval in people having antipsychotic medication to inform early value assessment: a systematic review
Westwood M, Armstrong N, Posadzki P, Noake C
Health Technol Assess . 2024 Mar; 28(19):1-94. PMID: 38551306
Background: The indication for this assessment is the use of the KardiaMobile six-lead electrocardiogram device for the assessment of QT interval-based cardiac risk in service users prior to the initiation...
5.
Software with artificial intelligence-derived algorithms for analysing CT brain scans in people with a suspected acute stroke: a systematic review and cost-effectiveness analysis
Westwood M, Ramaekers B, Grimm S, Armstrong N, Wijnen B, Ahmadu C, et al.
Health Technol Assess . 2024 Mar; 28(11):1-204. PMID: 38512017
Background: Artificial intelligence-derived software technologies have been developed that are intended to facilitate the review of computed tomography brain scans in patients with suspected stroke. Objectives: To evaluate the clinical...
6.
Correction: Belimumab for Treating Active Autoantibody‑Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Otten T, Riemsma R, Wijnen B, Armstrong N, Stirk L, Gordon C, et al.
Pharmacoeconomics . 2023 Sep; 41(11):1551. PMID: 37665503
No abstract available.
7.
A systematic review of clinical effectiveness and safety for historical and current treatment options for metachromatic leukodystrophy in children, including atidarsagene autotemcel
Armstrong N, Olaye A, Noake C, Pang F
Orphanet J Rare Dis . 2023 Aug; 18(1):248. PMID: 37644601
Objective: To understand the benefit-risk profile for historical and current treatments for MLD. Methods: A systematic review was conducted on the effectiveness, safety, and costs of MLD treatments: allogeneic haematopoietic...
8.
Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Witlox W, Grimm S, Howick J, Armstrong N, Ahmadu C, McDermott K, et al.
Pharmacoeconomics . 2023 May; 41(8):857-867. PMID: 37129774
The National Institute for Health and Care Excellence (NICE) invited the manufacturer (Celgene) of oral azacitidine (ONUREG), as part of the Single Technology Appraisal (STA) process, to submit evidence for...
9.
Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Orozco Leal G, Armstrong N, Kernohan A, Ahmadu C, Coughlan D, McDermott K, et al.
Pharmacoeconomics . 2023 Mar; 41(7):741-750. PMID: 36952138
The National Institute for Health and Care Excellence (NICE) invited the manufacturer (Eli Lilly) of abemaciclib (Verzenios) to submit evidence for the clinical and cost effectiveness of this drug in...
10.
Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Al Khayat M, Armstrong N, Howick J, OMeara S, Posadzki P, Ryder S, et al.
Pharmacoeconomics . 2023 Feb; 41(4):353-361. PMID: 36757608
The National Institute for Health and Care Excellence (NICE) invited the manufacturer (Roche) of pralsetinib (Gavreto), as part of the single technology appraisal (STA) process, to submit evidence for the...